NIH Funding Opportunities
Each year, the National Institutes of Health (NIH) invests more than $30 billion in medical research funding to a variety of research-related programs. NIH expects to spend an estimated $488 million to support pain research. APS monitors the NIH’s Funding Opportunity Announcements (FOAs) for opportunities specific to pain.
Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01)
The Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01) grant aims to fund applications designed to assess the clinical value of adjuncts prescribed to chronic pain patients together with opioid analgesics. Adjuncts of interest are either approved by the U.S. Food and Drug Administration (FDA) or have previously been studied as an investigational new drug. Studies with adjuncts of interest should be focused on enhancing analgesia rather than on reducing an adverse effect. A secondary purpose is to increase awareness among opioid prescribers of the potential value of adjunctive therapies by focused data dissemination.
Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42)
The Development of Opioid and Adjuvant Fixed Combination Dosage Forms for the Treatment of Chronic Pain with Reduced Addiction Potential (R41/R42) opportunity seeks small business organizations to develop opioid and adjuvant drug combinations within a single dosage form for treatment of a pain condition. The drug combination should provide improved analgesia when compared with the same dose (morphine equivalents) of opioid monotherapy. Such dosage forms should minimize opioid exposure while optimizing analgesia to reduce risk of addiction and limit severity of other opiate adverse effects.
Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R33)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory (R33) clinical trial grant applications that focus on the early phases of natural product development, during which basic and mechanistic research is translated into clinically testable hypotheses and tested in healthy volunteers or a clinical population. In this approach, clinical trials should be designed to increase knowledge of the use of the intervention, the underlying condition, and the mechanism of action through which the natural product produces clinical benefit. Applications for this FOA must have preliminary data demonstrating that the natural product has an impact on a biological signature in humans and that the natural product is bioavailable to exert this effect in humans. This FOA provides support for studies to confirm the natural product's effect on the biological signature in a larger sample and assess the relationship between the biological signature and changes in functional outcomes or clinical symptoms.
Neurobiology of Migraine (R01)
This FOA for the Neurobiology of Migraine (R01) grant is issued by the National Institute of Neurological Disorders and Stroke (NINDS) in conjunction with the National Institutes of Health (NIH) Pain Consortium. It solicits R01 grant applications from institutions and organizations to perform innovative research that will elucidate the mechanisms underlying migraine; expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression; and explore new therapeutic targets and therapies for acute migraine management and longer term prevention.
Self-Management for Health in Chronic Conditions (R01)
The purpose of this initiative is to support research in self-management focused across conditions. A recent report from the Institute of Medicine (IOM) identifies the epidemic of chronic condition as the nation's leading health challenge and calls for cross-cutting, coordinated public health actions for "living well with chronic illness". This Funding Opportunity Announcement (FOA) addresses that recommendation by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses/conditions. Self-management is the ability of the individual, in conjunction with family, community, and healthcare professionals, to manage symptoms, treatments, lifestyle changes, and psychosocial, cultural, and spiritual consequences associated with a chronic illness or condition.
Mechanisms, Models, Measurement, & Management in Pain Research (R01)
The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.
Phased Innovation Award for Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R21/R33)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage Phased Innovation (R21/R33) grant applications that focus on the early phases of natural product development, during which basic and mechanistic research is translated into clinically testable hypotheses and tested in healthy volunteers or a clinical population. In this approach, clinical studies and trials should be designed to increase knowledge of the use of the intervention, the underlying condition and the mechanism of action through which the natural product produces clinical benefit.
Research on Chronic Overlapping Pain Conditions (R01)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions.
Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness (R01)
This funding opportunity seeks to update the randomized control trial (RCT) design using novel research methods that are practical, innovative, and hold promise for producing more effective outcomes. Novel clinical research designs, applied to symptom management trials, may identify those treatment strategies that best alter the course of symptom burden in chronic illness by addressing the issues of varied treatment responses across patients, subject retention, and adherence to treatment regimens. For example, "sequential multiple assignment randomization trials" (SMART) design have been used successfully to develop dynamic treatment regimens for alcohol, depression and HIV infection but are not widely used in symptom management trials. The approach is pragmatic in that it mimics clinical practice by allowing a re-evaluation of treatment options based on an individual's progress towards treatment goals. The levels or inclusion of intervention components are tailored in response to individual characteristics or progress toward a treatment goal. Subjects may be randomly assigned several times to varying amounts and types of intervention components based on predetermined decision rules. This "sequential decision making" process allows for the initial intervention to be adapted and provides subjects with options for achieving a favorable outcome. A "Multiphase optimization strategy "(MOST) could also prove useful when applied to symptom management trials. This design leads to identification of a likely best intervention that can be evaluated at optimal levels in an RCT, through an iterative process of empirical research and discovery. In addition large scale Electronic Health Records (EHR) enabled research and other data mining efforts to identify likely best interventions that could be further tested in clinical trials is needed. The screening of viable treatment regimens and strategies from observational databases has the potential to find patterns of treatment and perhaps the optimal, naturalistic sequencing strategies used in current practice for managing symptoms. These natural trends in treatment variation may form the basis of explicit dynamic treatment regimens that can be tested in comparative trials. Finally comparative effectiveness research is needed to enhance trials that seek to determine the most potent intervention(s) for symptom prevention and management in chronic illness. Determining these interventions through comparative effectiveness research will inform healthcare decisions by providing evidence on the benefits and harms of different treatment strategies.